The current study shows that ganetespib, a selective and highly potent Hsp90 inhibitor, inhibits clonogenic survival in NSCLC cells, and synergizes the efficacy of irradiation. This provided the motivation to explore the combination of ganetespib with CRT to improve the clinical outcomes of unresectable NSCLC. When it was tested with CRT, ganetespib was able to sensitize some cell lines, but in others it had either no radiation sensitization effect or even abrogated the CRT effect. Our data cautions the assumption that drugs that sensitize to radiation would also sensitize to CRT. Rigorous and systematic preclinical testing of drugs must be done in the clinical context in which the disease is being treated. Identifying ways to circumvent this variable effect or predictive biomarkers will be needed for optimal translation of radiation sensitizing drugs to the clinical setting.
Introduction
Lung cancer is the leading cause of cancer death in the United States and has a 5-year relative survival rate of only 16% (1) . Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and the lack of significant treatment advance is related to the highly resistant nature of this disease. While chemotherapy provides only useful palliation for stage IV NSCLC, the treatment of locally advanced, unresectable NSCLC is with curative intent using concomitant chemotherapy and radiotherapy (chemoradiotherapy, CRT), which produces longer overall survival than sequential chemotherapy and radiation therapy (2) (3) (4) (5) (6) , but the outcomes remain poor. The median survival ranges from 17-28 months, despite significantly increased toxicity of the combination therapy. There is a strong need to improve therapy efficacy in NSCLC without substantially increasing normal tissue toxicity. Indeed, recent clinical trials have investigated the combination of CRT with molecularly targeted agents, either with angiogenesis inhibitors or with EGFR targeting agents. Unfortunately, either due to intolerable toxicities (7) or to lack of efficacy (8) , these trials have not advanced the management of this disease.
Hsp90 is a molecular chaperone protein ubiquitously present in cells; however its function is critically important for the maintenance of cancer cell growth (9, 10) . Inhibiting its function has been extensively studied for its potent antitumor effect (9, 11, 12 ). An attractive feature of targeting Hsp90 is that the cytotoxicity of Hsp90 inhibitors is tumor selective (13) . Hsp90 inhibition has also been known to be radiation sensitizing on tumor cells (14-25). Some of these studies indicated that the radiation sensitization is also tumor selective since normal cells are not affected (14, 15, 17) . However, the clinical development of Hsp90 inhibitors has been hampered by the severe toxicities of first generation inhibitors, including severe ocular and hepatic toxicities (26, 27).
Ganetespib, a second generation Hsp90 inhibitor with little to no ocular or hepatic toxicities, has been safely used in thousands of patients in over 60 clinical trials internationally. A completed phase II randomized trial in stage IV NSCLC combining ganetespib with docetaxel compared to docetaxel alone has demonstrated efficacy signal in a subgroup of patients (28), and therefore it was further tested in a phase III randomized trial (GALAXY II) (NCT01798485). Despite the safety and promising efficacy of this drug in advanced NSCLC, the experience of combining ganetespib with CRT is limited. While radiation sensitizing effect is well known for this class of inhibitors, one simply cannot assume that synergy could be seen with CRT. This was once assumed for EGFR inhibitors when preclinical studies demonstrated synergy with radiotherapy alone (29, 30), but ultimately failed in a number of phase III clinical trials when EGFR targeting agents were combined with CRT in oropharyngeal cancer, esophageal cancer, and NSCLC (8, 31, 32) . While this manuscript was under preparation, Gomez-Casal et al. reported the HSP90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells (33) , however whether ganetespib enhanced therapeutic effects of chemoradiotherapy was not demonstrated. The purpose of the current study is to evaluate the cytotoxic action of the combination of radiation with ganetespib and test its potential to synergize with CRT for the treatment of NSCLC.
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The human non-small lung cancer cell lines H460, A549, H1299, H1650, H358 and H2087 cells were all obtained from the American Type Culture Collection (ATCC) and routinely maintained in RPMI-1640 medium supplemented with 10% FBS, and 10,000 U/mL of penicillinstreptomycin. Cell lines were authenticated at Characterized Cell Line Core Facility at MD Anderson Cancer Center using the Short Tandem Repeat method every 6 months of use in the
was provided by Synta Pharmaceuticals Corp. Cells and animals were irradiated with a JL Shepherd Mark I-68A
137
Cs irradiator with 137 Cs sources at the doses from 0-6 Gy. The CesiumIrradiator output (cGy/min) was measured in-air using an ADCL (Accredited-DosimetryCalibration-Laboratory) calibrated ion-chamber. Dosimetry in Simulated-Irradiation-Geometry was performed employing Gafchromic-Film "EBT3". For Film-Dosimetry, mouse was simulated by dosimetrically-equivalent Gel "SuperFlab". EBT3 response in Simulated-Geometry versus inAir Reference-Calibration-Geometry provided dose-rate in mouse. The treatment set-up employed table, cerrobend-blockand mouse-restrainer on top. Cesium beam pointed up. All these pieces were provided with mutually inter-locking pins to ensure set-up reproducibility. For reduced penumbra, the block was provided with appropriate divergence.
Clonogenic survival assay (CSA) to determine ganetespib radiation sensitization effect
The effectiveness of the combination of ganetespib and ionizing radiation was assessed by CSA. H460, A549, H1299, and H1650 cells were seeded (100-2000 cells/well) in duplicate in 6-well plates. The medium was changed 16 hours after plating and the cells were treated with either vehicle (DMSO) or ganetespib (30 nM). Five hours following ganetespib treatment, the cells were subjected to irradiation at doses from 0-6 Gy. Twenty-four hours after ganetespib day, the medium was removed and cell colonies were stained with crystal violet (0.1% in 20% methanol) (Sigma-Aldrich, St. Louis, MO, USA). Colony numbers were assessed visually and colonies containing > 50 normal-appearing cells were counted. The surviving fraction was calculated using SigmaPlot 10.0 (San Jose, CA, USA).
Clonogenic survival assay for CRT with ganetespib
The combination effect of chemo radiation and ganetespib was assayed in vitro using clonogenic survival assay. Cells were seeded in 6-well plates 16 hours prior to treatment. The cells were treated by combination chemotherapy (Paclitaxel 3.51 nM with Carboplatin 24.23 nM) and/or ganetespib (30 nM) followed by radiation (2 Gy) after 4-5 hours. Drugs were washed out 24 hours after the treatment and the cells were maintained in normal cultural conditions for [12] [13] [14] [15] days. The colonies were stained by crystal violet (0.1% in 20% methanol) (Sigma-Aldrich, St.
Louis, MO, USA). Colony numbers were assessed visually and colonies containing > 50 normal-appearing cells were counted. The surviving fraction was calculated using GraphPad Prism 6 (La Jolla, CA, USA).
DNA repair foci formation assay
H460 and A549 cells were grown as monolayers on chamber slides with plastic bottom (Nunc Lab-Tek, Roskilde, Denmark) and were treated with DMSO or ganetespib (25 nM, 50 nM) 24 hours after seeding into culture chambers. Five hours after ganetespib treatment, the cells were subjected to irradiation at dose of 2 Gy. Thirty minutes, 4 hours, 24 hours and 48 hours after irradiation, cells were fixed in 4% paraformaldehyde in PBS for 15 min at room temperature and 
Reverse phase protein array (RPPA)
H460 and A549 cell lines were treated with vehicle (DMSO) or ganetespib (10 nM, 25 nM, 50 nM and 100 nM) with or without irradiation as described above and were harvested 24 hours after ganetespib treatment. Cell lysates were prepared using lysis buffer containing 1% Triton X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl 2 , 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na 3 VO 4 , 10% glycerol, containing freshly added protease and phosphatase inhibitors and 4x SDS sample buffer containing 40% Glycerol, 8% SDS, 0.25M Tris-HCL, pH 6.8. and 10% volume of 2-mercaptoethanol, arrayed on nitrocellulose-coated FAST slides (Whatman), and probed for a standard list of antibodies (34) .
Immunoblot analysis
H460 cell lines were treated with vehicle (DMSO) or ganetespib (25 nM, 50 nM) with or without irradiation (2 Gy, 4 Gy) as described above and were harvested 24 hours after genetespib treatment. After washing with ice-cold PBS, cell lysates were collected in RIPA Buffer (Life 
Statistical analysis
Statistical significance was assessed by Student's t-test (2 sample assuming unequal variances) and expressed as standard mean error. A difference was considered significant if p < 0.05.
RPPA statistical analysis used two-way analysis of variance (ANOVA) performed on a markerby-marker base to test for the interaction between radiation and drug treatment and one-way ANOVA for drug only effect. Pairwise comparisons between different drug doses were done using Tukey's honest significance (HSD) Test with 95% family-wise confidence level. To control for multiple testing, the resulting p-values, computed from test statistics applied, were modeled using a beta-uniform mixture (BUM) model in order to select p-value cutoffs according to pre-defined false discovery rates (FDRs). All statistical analyses of RPPA data were performed using R (version R3.1.0) and Bioconductor packages (http://www.r-project.org/).
Results

Ganetespib sensitizes NSCLC cells to radiation.
We assessed the ability of ganetespib to radiosensitize human NSCLC cells of varying genetic backgrounds using clonogenic survival curve assays. We evaluated the Kras mutant/p53 wild type cells H460 and A549, Kras wild type/p53 mutant cells H1650 cells, and the Kras wild type/p53 null H1299 cell lines. Cells were exposed to ganetespib at 30 nM for 5 hours, subsequently irradiated with gamma-rays and incubated for a further 19 hours in the presence of ganetespib. Irradiation in combination with ganetespib had a strong radiosensitizing effect on H460 and H1299 cells. Moderate sensitizing effects of ganetespib were observed for the A549 
and H1650 cells (Figure 1 A-D) . The radiosensitivity enhancement ratios at a survival rate of 50% were 1.87 in the H460 cell, 1.67 in the A549, 1.65 in H1650 and 2.4 in H1299. The results indicated that ganetespib can potentiate the radiation effect in different NSCLC cells.
Ganetespib inhibits radiation-induced DNA damage repair foci in NSCLC cancer cells. Double-strand DNA breaks induced by radiation, if unrepaired, can lead to genomic instability and cell death. To determine if radiation induced DNA damage repair can be hampered by ganetespib, we measured the DNA damage repair response by evaluating 53BP1 foci formation (Figure 2A-C) . In both the H460 and A549 cells, a substantial rise in 53BP1 foci formation is seen after 30 minutes of 2 Gy radiation for both the IR alone group and the IR+ganetespib group, but not apparent with ganetespib alone. While this effect is sustained at 4 hours, by 24 hours, the number of foci was reduced in the IR alone group but not to the same level as the ganetespib alone group. However, in both cell lines, the number of foci in the cells exposed to both ganetespib and radiation was sustained significantly longer compared with radiation alone at both the 24 and 48 hour time points. This suggests that ganetespib impairs the repair of radiation-induced double-strand DNA breaks.
G2/M arrest induced by irradiation is further intensified by ganetespib pretreatment.
As Hsp90 inhibitors are known to affect the cell cycle checkpoint (19, 21-24, 35, 36) , as does irradiation, which causes a G1/S arrest in P53 WT cells (37), we next determined the interaction of radiation with ganetespib on the cell cycle effects in both H460 and A549 cells (Figure 3A-D) . Figure 3A) . In addition to oncogenic proteins, ganetespib pretreatment followed by radiation also altered the expression levels of checkpoint proteins (Figure 4A-D,   Supplemental Figure 3B ). Ganetespib dose-dependently upregulated pCDC2 (pCDK1), but in combination with radiation there was instead a downregulation of pCDC2 at higher ganetespib levels. CDC2 is known to be involved in the G2/M checkpoint by regulating the activity of cyclin-dependent kinase inhibitor p21 which regulates G2/M transition. Ganetespib combined with radiation reduced the activity of phospho-p90RSK and phospho-S6, which is known as a regulator of CDC2 (Figure 4A-D, Supplemental Figure 3B ) at the dose of radiation (2-6 Gy)
Research. and ganetespib (25-100 nM). In A549 cells, cell cycle checkpoint proteins p21, p27, Chk1, Rb and phospho-S6 are also altered after the combined treatment (Figure 4C-D) . Ganetespib combined with radiation also increased cleaved caspase 7 and caspase 9 and DNA damage repair protein phospho-γH2AX that were not apparent with radiation alone (Supplemental Figure 3B) . Apoptosis was also determined by Annexin V-PI staining and flow cytometry analysis (Supplemental Figure 4 A-B) . There was a significant increase in the percentage of apoptotic cells with ganetespib treatment alone, an effect that was not enhanced with radiation.
Ganetespib demonstrated variable sensitizing effects with CRT in vitro and in vivo
Since CRT is the standard treatment for unresectable locally advanced NSCLC, adding a radiation sensitizer like ganetespib may improve clinical outcomes. In order to assay whether ganetespib enhances the treatment efficacy of CRT, we performed clonogenic survival assay using A549 and H460 (Figure 5A-B) . Robust clonogenic survival reduction was again seen in both cell lines when treated with ganetespib and IR. When chemotherapy was added, ganetespib was able to further enhance treatment efficacy for both chemotherapy and CRT in H460 cells but not in A549 cells. In A549, there was even a paradoxical increase in clonogenic survival when ganetespib was added to chemotherapy or CRT. Since A549 and H460 are both p53 wild-type cells, we tested two cell lines that harbored p53 mutations, H2087 and H358 (Figure 5 C-D) .
While ganetespib was again able to sensitize both of the cell lines to radiation, this was no longer apparent in the H2087 cells when co-treated with chemotherapy.
Next, we assessed the effect of ganetespib on anti-tumor treatment sensitivity in vivo compared to CRT alone. For this, we established a treatment protocol that reflected a shortened version of what's done clinically for unresectable NSCLC using fractionated daily 2 Gy radiation and concurrent chemotherapy with carboplatin and paclitaxel for 5 days, followed by consolidation chemotherapy alone for the second week. We compared this "standard therapy" to chemotherapy alone or radiation alone, with or without two doses of once-weekly ganetespib.
As shown in Figure 6A , in H460 xenografts, chemotherapy alone showed only minimal tumor growth inhibition, but when combined with ganetespib, the anti-tumor effect of chemotherapy was significantly increased. As expected, combined CRT had much stronger anti-tumor effect than either chemotherapy or radiation alone. However, ganetespib added to CRT produced the greatest tumor growth delay ( Figure 6A ). The addition of ganetespib to CRT delayed tumor growth by 7 days compared with CRT and by 17 days compared with non-treated control.
To determine if the DNA damage and cytotoxic effects of treatment in vivo could be compared to what we saw in vitro, we performed immunohistochemical staining for 53BP1 foci and cleaved caspase 7 on tumors removed at the end of the first 5 days of treatment. Compared to all the treatment groups, the tumors treated with the combination of ganetespib with CRT had significantly higher levels of P53BP1 foci and cleaved caspase 7 levels (Supplemental Figure   5 ). These results demonstrate that the enhanced DNA damage and cytotoxic effect of ganetespib with radiation seen in vitro could be further enhanced with concurrent CRT. effect on preventing tumor regrowth, but when ganetespib was added to CRT it caused rapid tumor progression after an initial period of tumor control.
Discussion
In clinical radiotherapy, tumor radioresistance is one of the causes of local failure after radiotherapy. The development of drugs that can enhance the sensitivity of tumor cells to radiation is of great importance to improve the outcomes of lung cancer therapy. Although there are many studies that have focused on the development of radiosensitizers, the targeted agents that have been tested clinically, namely vascular targeting drugs and EGFR inhibitors, have so far not been clinically useful when combined with CRT for NSCLC. Unfortunately most of rationale for the combination has been based on preclinical studies using radiation alone. The best example was the EGFR targeting drugs. It has been well established in preclinical studies that EGFR inhibition sensitizes radiation for multiple tumor types, including head and neck cancer and NSCLC(29, 40). The approach seemed promising when a survival benefit was demonstrated for cetuximab when it was combined with radiotherapy compared to radiotherapy alone in head and neck cancer in a phase III randomized trial (32) . Unfortunately, the benefit of cetuximab disappeared when it was combined with CRT, as shown in two large randomized trials for head and neck cancer (RTOG 0522 (41)) and unresectable NSCLC (RTOG 0617 (8)).
This experience highlights the importance of critically evaluating radiosensitizers in preclinical models that at least modestly reflect the treatment regime used in the clinical setting. Studies have shown that one of the causes of sensitization could be inhibition of DNA double strand break (DSB) repair (17) (18) (19) (20) (21) 36) . Checkpoint arrest mainly at G2/M phase has also been suggested as a cause of radiosensitization with Hsp90 inhibitors (19) (20) (21) (22) (23) (24) 36) . Radiosensitization effect in vivo by Hsp90 inhibitors has also been demonstrated (14, 21, 23). These data strongly suggest that targeting Hsp90 with its inhibitors represents a promising strategy for enhancing the sensitivity of cancer cells to radiation (19) (20) (21) (22) (23) (24) . Ganetespib is an investigational small molecule inhibitor of Hsp90 with favorable pharmacologic properties that distinguishes it from other firstand second-generation Hsp90 inhibitors in terms of potency, safety, and tolerability (27, 42).
Ganetespib has also been shown to possess robust antitumor activity against a variety of cancer types in preclinical studies, including lung, breast, and prostate (38, 43-47). In addition, it has been shown in NSCLC cell lines that a synergistic combinatorial benefit was seen with the taxanes such as paclitaxel or docetaxel (43) .
As expected, we demonstrated that ganetespib significantly reduced clonogenic survival of various lung cancer cell lines, attenuated DNA damage repair, induced cell cycle arrest by the enhanced upregulation of negative cell cycle regulators (p21 and/or p27) and/or downregulation of positive regulators (cyclins D1 and E, CDK1, CDK2 and CDK4) that was greater than either treatment alone. Since CRT with carboplatin and paclitaxel is the standard treatment regime for On the surface, the cell lines that do not respond to ganetespib when combined to CRT do not appear to be related to Kras or p53 mutation statuses. The mechanism for the variable effects of ganetespib in the various cell lines needs further investigation.
Our findings imply that only a subgroup of lung cancer patients may benefit from HSP90 inhibition when receiving CRT. This may warrant the need for a predictable biomarker that could potentially identify patients to receive or avoid HSP90 inhibitors in combination with chemotherapy or CRT. It is important to emphasize the fact that drugs which sensitize cancer cells to radiation may not have the same effect when added with chemotherapy or CRT. This may explain the failure of previous trials using EGFR inhibitors in combination with CRT as well as the recent futility closure of the GALAXY-II docetaxel-ganetespib trial in lung cancer.
Future development of the optimal drug and radiation combination needs to be tested in rigorous preclinical models within the context of clinically-relevant therapy combinations. 
